Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Return on Sales: 2014-2025

Historic Return on Sales for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to -0.33%.

  • Ascendis Pharma A's Return on Sales rose 93.00% to -0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.33%, marking a year-over-year increase of 93.00%. This contributed to the annual value of -1.04% for FY2024, which is 77.00% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Return on Sales stood at -0.33%, which was up 37.45% from -0.52% recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Return on Sales high stood at -0.33% for Q3 2025, and its period low was -122.03% during Q3 2021.
  • Over the past 3 years, Ascendis Pharma A's median Return on Sales value was -1.49% (recorded in 2024), while the average stood at -2.25%.
  • As far as peak fluctuations go, Ascendis Pharma A's Return on Sales crashed by 8,160bps in 2021, and later spiked by 10,729bps in 2022.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Return on Sales stood at -50.15% in 2021, then spiked by 3,885bps to -11.30% in 2022, then skyrocketed by 954bps to -1.76% in 2023, then surged by 73bps to -1.03% in 2024, then skyrocketed by 93bps to -0.33% in 2025.
  • Its Return on Sales was -0.33% in Q3 2025, compared to -0.52% in Q2 2025 and -0.92% in Q1 2025.